Analysts expect Nurix Therapeutics, Inc. to report revenue of 25.86 M for Q3 26, against a range of 24.03 M to 27.68 M. The most recent reported quarter, Q2 26, came in at 9.04 M, a 38.4% miss against the 14.67 M consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 12.59 M | 13.28 M | 18.45 M | 44.06 M | 7.89 M | 13.58 M | 6.25 M | 9.04 M | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | 12.28 M | 14.67 M | 12.82 M | 19.88 M | 16.45 M | 14.72 M | 14.36 M | 15.60 M | 27.68 M | 31.17 M | 15.90 M | 16.54 M | 38.92 M | 50.09 M | 41.01 M | 46.82 M | ||||||||||
| Low Estimate | 11.00 M | 12.39 M | 11.66 M | 16.32 M | 13.93 M | 13.76 M | 12.16 M | 13.74 M | 24.03 M | 26.89 M | 13.31 M | 14.01 M | 34.67 M | 44.02 M | 38.36 M | 43.60 M | ||||||||||
| Consensus Estimate | 11.64 M | 13.53 M | 12.24 M | 18.10 M | 15.19 M | 14.24 M | 13.26 M | 14.67 M | 25.86 M | 29.03 M | 14.61 M | 15.28 M | 36.79 M | 47.06 M | 39.69 M | 45.21 M |
Analysts expect Nurix Therapeutics, Inc. to report earnings per share of -0.57 for Q3 26, against a range of -0.60 to -0.54. The most recent reported quarter, Q2 26, came in at -0.81, a 8.0% miss against the -0.75 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -0.67 | -0.75 | -0.67 | -0.52 | -1.03 | -0.82 | -0.79 | -0.81 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | -0.69 | -0.66 | -0.77 | -0.70 | -0.80 | -0.79 | -0.78 | -0.71 | -0.54 | -0.08 | -0.51 | -0.54 | -0.51 | -0.05 | -0.16 | -0.19 | ||||||||||
| Low Estimate | -0.77 | -0.78 | -0.83 | -0.78 | -0.88 | -0.89 | -0.84 | -0.79 | -0.60 | -0.10 | -0.61 | -0.62 | -0.59 | -0.05 | -0.18 | -0.23 | ||||||||||
| Consensus Estimate | -0.73 | -0.72 | -0.80 | -0.74 | -0.84 | -0.84 | -0.81 | -0.75 | -0.57 | -0.09 | -0.56 | -0.58 | -0.55 | -0.05 | -0.17 | -0.21 |
Pull Wall Street consensus for Nurix Therapeutics, Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=NRIX&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "NRIX", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=NRIX&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();